In Conversation With… Prasad Kulkarni on a dengue monoclonal antibody

from Listen to The Lancet Infectious Diseases · host The Lancet

Prasad Kulkarni discusses a new Phase I trial in The Lancet Infectious Diseases on a dengue monoclonal antibody also known as VIS513 in healthy adults. In addition, he highlights the wider implications of this for dengue control and drug development.

Episode metadata supplied by the publisher feed · Published Feb 24, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

In Conversation With… Prasad Kulkarni on a dengue monoclonal antibody

0:00 18:53

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Listen to The Lancet Infectious Diseases?

This episode is 18 minutes long.

When was this Listen to The Lancet Infectious Diseases episode published?

This episode was published on February 24, 2024.

Can I download this Listen to The Lancet Infectious Diseases episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!